OncoMatch/Clinical Trials/NCT06224049
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Is NCT06224049 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including hNeo-T and Cyclophosphamide for t-cell lymphoma.
Treatment: hNeo-T · Cyclophosphamide · Fludarabine — Objective: To evaluate the safety and tolerability of hNeo-T injection in patients with relapsed or refractory EBV-positive T-cell lymphoma. Secondary objective: To evaluate the effectiveness of hNeo-T injection, and to evaluate the objective response rate (ORR) and disease control rate (DCR) by Lugano2014 criteria; Progression-free survival (PFS), duration of response (DOR), and overall survival (OS ) followed. Objective of the exploratory study: To investigate the in vivo process of hNeo-T injection and describe the activity and related biological functions of hNeo-T cells in vivo, including but not limited to.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — first-line or above
Disease progression after adequate first-line systemic treatment, or disease progression ≥2 cycles (PD) after first-line or above systemic systemic treatment, or ≥4 cycles without remission (CR or PR)
Lab requirements
Blood counts
ANC ≥1×10^9/L, PLT ≥75×10^9/L, HGB ≥80g/L
Kidney function
serum creatinine ≤1.5x ULN
Liver function
ALT and AST ≤3x ULN (≤5x ULN in liver metastasis subjects); total bilirubin ≤1.5x ULN, or <3x ULN for Gilbert's Syndrome
Cardiac function
LVEF ≥50%
Laboratory test results and vital organ functions meet the following requirements: ... see full criteria for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify